‘A very paternalistic attitude’: why is female desire still not taken seriously?
🤖AI Özeti
The article discusses the ongoing struggle for recognition of female sexual desire, particularly through the lens of the drug flibanserin, marketed as Addyi. Despite its FDA approval in 2015 for women with Hypoactive Sexual Desire Disorder, many women remain unaware of its existence and the societal stigma surrounding female libido persists. The documentary 'The Pink Pill' highlights the regulatory hurdles, sexism, and lack of medical education regarding female sexual health that have hindered progress in this area.
💡AI Analizi
📚Bağlam ve Tarihsel Perspektif
Flibanserin was initially developed as an antidepressant but was later recognized for its potential to treat low libido in women. Its journey through the FDA approval process was fraught with skepticism and gender bias, contrasting sharply with the quick acceptance of male sexual enhancement drugs. The documentary emphasizes the cultural and institutional barriers that continue to affect women's sexual health.
This article reflects the opinions and findings presented in the documentary 'The Pink Pill' and may not represent the views of all medical professionals.
Orijinal Kaynak
Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.
Kaynağı Görüntüleİlgili Haberler
Tümünü Gör
NewsAI Mobil Uygulamaları
Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.